key: cord-0847803-43cbu094 authors: Fraga, Montserrat; Moradpour, Darius; Artru, Florent; Romailler, Elodie; Tschopp, Jonathan; Schneider, Antoine; Chtioui, Haithem; Neerman-Arbez, Marguerite; Casini, Alessandro; Alberio, Lorenzo; Sempoux, Christine title: Hepatocellular Type II Fibrinogen Inclusions in a Patient with Severe COVID-19 and Hepatitis date: 2020-06-22 journal: J Hepatol DOI: 10.1016/j.jhep.2020.06.021 sha: 1c085d7924ff69930fd4ddc795f37c7a40175b59 doc_id: 847803 cord_uid: 43cbu094 nan A 62-year-old man without notable medical history was admitted to a regional hospital with high fever, cough and shortness of breath. Chest CT revealed bilateral ground-glass opacities consistent with viral pneumonia. SARS-CoV-2 infection was confirmed by positive RT-PCR on nasopharyngeal swab. Initial treatment comprised atazanavir and ceftriaxone. Four days later, the patient's condition deteriorated and he required endotracheal intubation. He was then transferred to our tertiary care center for further management. Antimicrobial therapy was replaced by hydroxychloroquine and then remdesivir as well as by piperacillin-tazobactam (Fig. 1) . Conventional lung protective ventilation with prone positioning was initiated. On day seven after transfer, despite antithrombotic prophylaxis with unfractionated heparin, bilateral segmental pulmonary embolism was diagnosed and therapeutic anticoagulation initiated. At that point, coagulation tests revealed slightly decreased prothrombin time (70%; reference range, 80-120%), explained by a mild constitutional isolated defect in factor VII, and Ddimers of 10,620 ng/ml (cut-off for venous thromboembolism, < 500 ng/ml) (Suppl. Table 1) . By day 20, plasma fibrinogen rose to 7.1 g/l (reference range, 2.0-4.0 g/l). The further course was complicated by ventilator-associated pneumonia treated with cefepime and then meropenem as well as by critical illness polyneuropathy. PCR for SARS-CoV-2 was negative on bronchoalveolar lavage performed on day 21. A tracheotomy was performed on day 24. In parallel, the patient developed hepatitis. On the day of admission to our center, Table 1 ). Synthetic liver cell function was preserved (factor V 140%). Antiviral medication and antibiotics had been stopped 20 days and 2 days prior to the peak of transaminases, respectively. The liver was normal on imaging, with patent portal and hepatic veins. Serologies and molecular testing for hepatitis B, C and E as well as herpes simplex, parvovirus B19, human herpesvirus 6, Epstein-Barr virus, and SARS-CoV-2 were negative. Blood PCR for cytomegalovirus (CMV) was positive at 50,800 copies/ml and ganciclovir at dose of 10 mg/kg/day was started, resulting in a drop of viremia to 2,100 copies/ml within 10 days. Liver biopsy performed on day 25 revealed a mild lymphoplasmocytic infiltrate in the portal tracts, without interface hepatitis or fibrosis, together with a few apoptotic hepatocytes scattered throughout the lobules. The presence of some hepatocyte mitoses and of numerous ceroid macrophages indicated that hepatitis had been ongoing for a while already. 3 There was no evidence of endotheliitis or hemophagocytosis, and there was no sinusoidal fibrin deposition. The more striking histological feature was the presence of numerous ground-glass hepatocytes with weakly eosinophilic cytoplasmic inclusions of various size, showing round or reniform shape and sharp edges ( Fig. 2A) . Periodic Acid Schiff (PAS) stain was negative (Fig. 2B) , as well as immunochemistry for hepatitis B surface antigen (not illustrated). The cytoplasmic inclusions strongly reacted with an anti-fibrinogen antibody (Fig. 2C ), demonstrating that they were composed mainly of fibrinogen. They were also positive, in a patchy pattern, for C-reactive protein (not illustrated). Immunochemistry for CMV was negative; PCR for CMV in the tissue was only weakly positive (200 copies/ml). At electron microscopy, the inclusions contained a homogenous, moderately electron dense granular material (Fig. 2D ). They were delineated, at least focally, by a membrane, arguing in favor of dilated endoplasmic reticulum (Fig. 2E) . Hence, the morphological picture suggested hepatocellular type II fibrinogen inclusions (1). Genetic analysis did not reveal any known mutations responsible for fibrinogen storage disease in exons 8 and 9 of the FGG gene. In the following, the patient's condition progressively improved and he could be successfully weaned from mechanical ventilation on day 37. On day 44, at the time of this writing, ALT has dropped to 384 U/l, with AST of 166 U/l, alkaline phosphatase of 323 U/l and normal total bilirubin. In a patient with severe COVID-19, we describe an unusual form of liver disease, characterized by a ground-glass appearance of the hepatocytes resulting from the pathological cytoplasmic accumulation of fibrinogen. The differential diagnosis of groundglass hepatocytes includes first the presence of hepatitis B surface antigen (HBsAg) in chronic hepatitis B infection that can be identified by specific immunohistochemistry (2). Then, most of the other types of ground glass inclusions are linked to the accumulation of abnormal glycogen granules and are therefore PAS positive (2) . They are observed in Lafora's disease, type IV glycogenosis and cyanamide aversion therapy in alcoholic patients (2) , and have also been more recently described as "polyglucosan-like" hepatocellular inclusions in patients under polypharmacotherapy (3). In our patient, the ground glass inclusions were PAS negative, which prompted us to think of the possibility of abnormal fibrinogen accumulation, confirmed by the strong immunohistochemical reaction with an antifibrinogen antibody, and by the electron microscopy feature of membrane-bound inclusions (1, 2). 4 Fibrinogen is a large, oligomeric glycoprotein complex produced in the liver and secreted into the blood. Fibrinogen Aα, Bβ and γ chains are encoded by the FGA, FGB and FGG genes, respectively. These are located on chromosome 4 and expressed almost exclusively in hepatocytes. Fibrinogen is converted by thrombin to fibrin, the most abundant component of a blood clot (4) (5) . Plasma fibrinogen levels are increased by mediators of the acute-phase inflammatory response, e.g. IL-6, or may be decreased as a result of consumption in disseminated intravascular coagulation. On the other side, mutations in fibrinogen genes cause congenital disorders that are typically associated with a-, hypo-, and/or dysfibrinogenemia (6) . In rare cases, a few mutations clustered in exons 8-9 of FGG result in the intracellular accumulation of misfolded fibrinogen in hepatocytes, chronic liver disease of various severity, and hypofibrinogenemia (7) . Of note, fibrinogen storage disease without hypofibrinogenemia, which corresponds to the clinical picture presented by our patient, has rarely been associated with acute infections in patients without any hereditary defect of fibrinogen (8-9). Our patient presented very high plasma fibrinogen levels, making the presence of a known FGG mutation very unlikely, as confirmed by genetic testing. Increased fibrinogen production likely played a key role in the hypercoagulable state and pulmonary embolism (10). Increased fibrin formation and lysis can account for the very high levels of D-dimers as observed in our patient. This has been previously associated with worse outcomes in patients with COVID-19 (11-13). Information on liver involvement in COVID-19 is limited to date (14) (15) (16) . Elevated transaminases have been noted in up to 53% of patients with COVID-19. Liver injury in patients with SARS-CoV-2 infection may be caused by direct viral effects or indirectly by the systemic inflammatory response, drug toxicity, hemodynamic alterations or other factors. It appears to be more prevalent in severe as compared to mild cases of COVID-19. Only few reports have assessed liver histology in COVID-19 (17) (18) (19) . Observed lesions include sinusoidal dilatation, mild portal and lobular inflammation, microvesicular steatosis or patchy necrosis. To our knowledge, a manifestation similar to the one documented in our patient has not been reported to date in the setting of SARS-CoV-2 infection. The histopathological substrate in our patient was an acute mostly lobular hepatitis with hepatocellular type II fibrinogen inclusions (9) associated with high plasmatic fibrinogen levels in a context of severe systemic inflammation. Based on the temporal relationships, none of the administered drugs could be unequivocally linked to ALT increase. However, it is possible that one of them or another as yet unidentified extrinsic or intrinsic factor impaired 5 fibrinogen secretion and contributed to intrahepatic accumulation as a "second hit". Of note, hydroxychloroquine impacts on lysosomal function, autophagy and the Golgi apparatus (20) (21) . Although our patient had been treated with hydroxychloroquine for only two days, one may speculate that this may have contributed to pathological hepatic accumulation of fibrinogen. A direct viral effect is less likely given the negative PCR results on nasopharyngeal swabs and bronchoalveolar lavage performed 10 days and four days prior to liver biopsy, respectively. In addition, SARS-CoV-2 does not appear to circulate systemically at relevant levels (22) . Experimental studies will have to confirm a cascade linking SARS-CoV-2-induced severe inflammation, hyperfibrinogenemia and an as yet unidentified additional factor impairing hepatic fibrinogen secretion with acquired fibrinogen storage disease and hepatitis. Fibrinogen inclusions in liver cells: a new type of ground-glass hepatocyte. Immune light and electron microscopic characterization Ground-glass hepatocytes: light and electron microscopy. Characterization of the different types Ground-glass, polyglycosan-like hepatocellular inclusions: a "new" diagnostic entity Fibrinogen gene regulation A circulating factor in search of its genetics architecture Congenital fibrinogen disorders Fibrinogen gamma chain mutations provoke fibrinogen and apolipoprotein B plasma deficiency and liver storage Fibrinogen storage disease without hypofibrinogenemia associated with acute infection Rethinking fibrinogen storage disease of the liver: Ground glass and globular inclusions do not represent a congenital metabolic disorder but acquired collective retention of proteins High levels of fibrinogen are associated with the risk of deep venous thrombosis mainly in the elderly Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study COVID-19-related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure Clinical characteristics of coronavirus disease 2019 in China Liver injury during highly pathogenic human coronavirus infections Liver injury in COVID-19: management and challenges Pathological study of the 2019 novel coronavirus disease (COVID-19) through post mortem core biopsies COVID-19 associated hepatitis complicating recent living donor liver transplantation Pathological findings of COVID-19 associated with acute respiratory distress syndrome Assembly and secretion of fibrinogen. Degradation of individual chains Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion Virological assessment of hospitalized patients with COVID-2019 The authors gratefully acknowledge C. Chapuis for electron microscopy as well as H.Goubin D. Maison and N. Piazzon, for immunochemistry.